{"nodes":[{"data":{"id":"Protein_06fde557217dbf75b819191c370cb967","class":"macromolecule","label":"MAP3K20","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_06fde557217dbf75b819191c370cb967.info.1","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_06fde557217dbf75b819191c370cb967.state.2","class":"state variable","state":{"variable":"","value":"P"}}],"unitsOfInformation":[],"bbox":{"x":221.77692,"y":165.34439,"w":48,"h":25},"metadata":[["bp:displayName","MLK7"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85485"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00696"],["bp:db","protein modification ontology"]]],["bp:comment","DATA_SOURCE=CellDesigner"],["bp:term","phosphorylated residue"],["bp:term","phosres"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85486"]]],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation","MOD_RES 567 567 Phosphoserine."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85484"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85484"]]}},{"data":{"id":"Protein_3e52553453b56c182c0d978bccafe30a","class":"macromolecule","label":"CCND1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_3e52553453b56c182c0d978bccafe30a.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":670.48846,"y":603.6328,"w":48,"h":25},"metadata":[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P24385"]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]}},{"data":{"id":"Complex_55ee9b8dc7db84a0b99df71bdb152cd0","class":"complex","label":"p38 gamma/SNTA1","parent":"","clonemarker":false,"stateVariables":[{"id":"Complex_55ee9b8dc7db84a0b99df71bdb152cd0.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":608.5107,"y":317.9804,"w":52,"h":64},"metadata":[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation","MOD_RES 184 184 Phosphoserine."]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]}},{"data":{"id":"Protein_e8573b29f47679c5faaa4c8c9f601e33_Complex_55ee9b8dc7db84a0b99df71bdb152cd0","class":"macromolecule","label":"MAPK12","parent":"Complex_55ee9b8dc7db84a0b99df71bdb152cd0","clonemarker":false,"stateVariables":[{"id":"Protein_e8573b29f47679c5faaa4c8c9f601e33_Complex_55ee9b8dc7db84a0b99df71bdb152cd0.info.1","class":"state variable","state":{"variable":"183","value":"opthr"}},{"id":"Protein_e8573b29f47679c5faaa4c8c9f601e33_Complex_55ee9b8dc7db84a0b99df71bdb152cd0.state.2","class":"state variable","state":{"variable":"185","value":"optyr"}}],"unitsOfInformation":[],"bbox":{"x":608.5107,"y":335.4804,"w":48,"h":25},"metadata":[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P53778"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P53778"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P53778"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P53778"]]],["bp:standardName","Mitogen-activated protein kinase 12"],["bp:xref","Mitogen-activated protein kinase 12"],["bp:xref","Mitogen-activated protein kinase 12"],["bp:organism","Mitogen-activated protein kinase 12"],["bp:displayName","MK12_HUMAN"],["bp:name","ERK6"],["bp:name","MAP kinase p38 gamma"],["bp:name","MAPK 12"],["bp:name","MAP kinase 12"],["bp:name","2.7.11.24"],["bp:name","Stress-activated protein kinase 3"],["bp:name","MAPK12"],["bp:name","ERK-6"],["bp:name","SAPK3"],["bp:name","Extracellular signal-regulated kinase 6"],["bp:name","Mitogen-activated protein kinase p38 gamma"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1CM8_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03868_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34241N_identity"],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway. MAPK12 isone of the four p38 MAPKs which play an important role in thecascades of cellular responses evoked by extracellular stimulisuch as proinflammatory cytokines or physical stress leading todirect activation of transcription factors such as ELK1 and ATF2.Accordingly, p38 MAPKs phosphorylate a broad range of proteins andit has been estimated that they may have approximately 200 to 300substrates each. Some of the targets are downstream kinases suchas MAPKAPK2, which are activated through phosphorylation andfurther phosphorylate additional targets. Plays a role in myoblastdifferentiation and also in the down-regulation of cyclin D1 inresponse to hypoxia in adrenal cells suggesting MAPK12 may inhibitcell proliferation while promoting differentiation. PhosphorylatesDLG1. Following osmotic shock, MAPK12 in the cell nucleusincreases its association with nuclear DLG1, thereby causingdissociation of DLG1-SFPQ complexes. This function is independentof its catalytic activity and could affect mRNA processing and/orgene transcription to aid cell adaptation to osmolarity changes inthe environment. Regulates UV-induced checkpoint signaling andrepair of UV-induced DNA damage and G2 arrest after gamma-radiation exposure. MAPK12 is involved in the regulation of SLC2A1expression and basal glucose uptake in L6 myotubes; and negativelyregulates SLC2A4 expression and contraction-mediated glucoseuptake in adult skeletal muscle. C-Jun (JUN) phosphorylation isstimulated by MAPK14 and inhibited by MAPK12, leading to adistinct AP-1 regulation. MAPK12 is required for the normalkinetochore localization of PLK1, prevents chromosomal instabilityand supports mitotic cell viability. MAPK12-signaling is alsopositively regulating the expansion of transient amplifyingmyogenic precursor cells during muscle growth and regeneration.{ECO:0000269|PubMed:10848581, ECO:0000269|PubMed:14592936,ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:20605917,ECO:0000269|PubMed:21172807, ECO:0000269|PubMed:8633070,ECO:0000269|PubMed:9430721}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10212242}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10508788};Note=Binds 2 magnesium ions. {ECO:0000269|PubMed:10508788};ENZYME REGULATION: Activated by phosphorylation on threonine andtyrosine. MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for theactivation of MAPK12 induced by environmental stress, whereasMAP2K6/MKK6 is the major MAPK12 activator in response to TNF-alpha. {ECO:0000269|PubMed:10212242, ECO:0000269|PubMed:9430721}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=37 uM for ATP {ECO:0000269|PubMed:10212242};KM=313 uM for EGFR substrate peptide{ECO:0000269|PubMed:10212242};KM=254 uM for GST-ATF2 {ECO:0000269|PubMed:10212242};SUBUNIT: Monomer. Interacts with the PDZ domain of the syntrophinSNTA1. Interacts with SH3BP5. Interacts with LIN7C, SCRIB andSYNJ2BP (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Mitochondrion.Note=Mitochondrial when associated with SH3BP5. In skeletal musclecolocalizes with SNTA1 at the neuromuscular junction andthroughout the sarcolemma (By similarity). {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P53778-1; Sequence=Displayed;Name=2;IsoId=P53778-2; Sequence=VSP_055224;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in skeletal muscle and heart.{ECO:0000269|PubMed:11991731, ECO:0000269|PubMed:8633070}.INDUCTION: Expression of MAPK12 is down-regulation by MAPK14activation. {ECO:0000269|PubMed:17724032}.DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K3/MKK3and MAP2K6/MKK6, which activates the enzyme.{ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:17724032}.PTM: Ubiquitinated. Ubiquitination leads to degradation by theproteasome pathway. {ECO:0000269|PubMed:17724032}.DISEASE: Note=MAPK is overexpressed in highly metastatic breastcancer cell lines and its expression is preferentially associatedwith basal-like and metastatic phenotypes of breast tumor samples.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK12ID41290ch22q13.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002960"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6300"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_658"],["bp:comment","MK12_HUMAN Reviewed; 367 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85498"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85498"]]}},{"data":{"id":"Protein_45fcbaf0216e4454347283da3444621d_Complex_55ee9b8dc7db84a0b99df71bdb152cd0","class":"macromolecule","label":"SNTA1","parent":"Complex_55ee9b8dc7db84a0b99df71bdb152cd0","clonemarker":false,"stateVariables":[{"id":"Protein_45fcbaf0216e4454347283da3444621d_Complex_55ee9b8dc7db84a0b99df71bdb152cd0.info.1","class":"state variable","state":{"variable":"193","value":"opser"}},{"id":"Protein_45fcbaf0216e4454347283da3444621d_Complex_55ee9b8dc7db84a0b99df71bdb152cd0.state.2","class":"state variable","state":{"variable":"201","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":608.5107,"y":300.4804,"w":48,"h":25},"metadata":[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]}},{"data":{"id":"Protein_58ad31ea01610e5c631e55d7e995ea39","class":"macromolecule","label":"MAPT","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_58ad31ea01610e5c631e55d7e995ea39.info.1","class":"state variable","state":{"variable":"396","value":"opser"}},{"id":"Protein_58ad31ea01610e5c631e55d7e995ea39.state.2","class":"state variable","state":{"variable":"202","value":"opser"}},{"id":"Protein_58ad31ea01610e5c631e55d7e995ea39.info.3","class":"state variable","state":{"variable":"205","value":"opthr"}},{"id":"Protein_58ad31ea01610e5c631e55d7e995ea39.state.4","class":"state variable","state":{"variable":"422","value":"opser"}},{"id":"Protein_58ad31ea01610e5c631e55d7e995ea39.info.5","class":"state variable","state":{"variable":"181","value":"opthr"}}],"unitsOfInformation":[],"bbox":{"x":535.3435999999999,"y":577.0347,"w":85,"h":25},"metadata":[["bp:displayName","Tau"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85437"],["bp:featureLocation",[["bp:sequencePosition","396"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_20376"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85435"],["bp:featureLocation",[["bp:sequencePosition","202"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_28908"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85436"],["bp:featureLocation",[["bp:sequencePosition","205"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_17653"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85436"],["bp:featureLocation",[["bp:sequencePosition","205"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_17653"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85436"],["bp:featureLocation",[["bp:sequencePosition","205"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_17653"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85436"],["bp:featureLocation",[["bp:sequencePosition","205"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_17653"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85433"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85433"]]}},{"data":{"id":"Protein_ac3f1d876372d67ec808fa0e78f8f12e","class":"macromolecule","label":"EEF2K","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":559.2186,"y":660.25903,"w":48,"h":25},"metadata":[["bp:displayName","eEF2K"],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 353 353 Phosphothreonine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","353"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 474 474 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","474"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 66 66 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 66 66 Phosphoserine; by autocatalysis."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11841"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_11841"]]}},{"data":{"id":"Protein_edfcca4699b5b1e52a7a1c42a1af5814","class":"macromolecule","label":"EEF2K","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_edfcca4699b5b1e52a7a1c42a1af5814.info.1","class":"state variable","state":{"variable":"359","value":"opser"}},{"id":"Protein_edfcca4699b5b1e52a7a1c42a1af5814.state.2","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":536.98096,"y":817.14166,"w":48,"h":25},"metadata":[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","477"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]}},{"data":{"id":"Protein_c6374c3394d83a9ecd4b7c9f5c37582e","class":"macromolecule","label":"MAPK13","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":282.16766,"y":794.03076,"w":48,"h":25},"metadata":[["bp:displayName","p38 delta"],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 180 180 Phosphothreonine; by MAP2K3, MAP2K4,MAP2K6 and MAP2K7."],["bp:featureLocation",[["bp:sequencePosition","180"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 47 47 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","47"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 182 182 Phosphotyrosine; by MAP2K3, MAP2K4,MAP2K6 and MAP2K7."],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 182 182 Phosphotyrosine; by MAP2K3, MAP2K4,MAP2K6 and MAP2K7."],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 182 182 Phosphotyrosine; by MAP2K3, MAP2K4,MAP2K6 and MAP2K7."],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 182 182 Phosphotyrosine; by MAP2K3, MAP2K4,MAP2K6 and MAP2K7."],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Mitogen-activated protein kinase 13"],["bp:xref","Mitogen-activated protein kinase 13"],["bp:xref","Mitogen-activated protein kinase 13"],["bp:organism","Mitogen-activated protein kinase 13"],["bp:displayName","MK13_HUMAN"],["bp:name","MAP kinase 13"],["bp:name","MAPK13"],["bp:name","PRKM13"],["bp:name","MAP kinase p38 delta"],["bp:name","Mitogen-activated protein kinase p38 delta"],["bp:name","2.7.11.24"],["bp:name","MAPK 13"],["bp:name","Stress-activated protein kinase 4"],["bp:name","SAPK4"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_714"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5603"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002745"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5603"],["bp:comment","MK13_HUMAN Reviewed; 365 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_09113_identity"],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway. MAPK13 isone of the four p38 MAPKs which play an important role in thecascades of cellular responses evoked by extracellular stimulisuch as proinflammatory cytokines or physical stress leading todirect activation of transcription factors such as ELK1 and ATF2.Accordingly, p38 MAPKs phosphorylate a broad range of proteins andit has been estimated that they may have approximately 200 to 300substrates each. MAPK13 is one of the less studied p38 MAPKisoforms. Some of the targets are downstream kinases such asMAPKAPK2, which are activated through phosphorylation and furtherphosphorylate additional targets. Plays a role in the regulationof protein translation by phosphorylating and inactivating EEF2K.Involved in cytoskeletal remodeling through phosphorylation ofMAPT and STMN1. Mediates UV irradiation induced up-regulation ofthe gene expression of CXCL14. Plays an important role in theregulation of epidermal keratinocyte differentiation, apoptosisand skin tumor development. Phosphorylates the transcriptionalactivator MYB in response to stress which leads to rapid MYBdegradation via a proteasome-dependent pathway. MAPK13 alsophosphorylates and down-regulates PRKD1 during regulation ofinsulin secretion in pancreatic beta cells.{ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11943212,ECO:0000269|PubMed:15632108, ECO:0000269|PubMed:17256148,ECO:0000269|PubMed:18006338, ECO:0000269|PubMed:18367666,ECO:0000269|PubMed:20478268, ECO:0000269|PubMed:9731215}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation on threonine andtyrosine by dual specificity kinases, MAP2K3/MKK3, MAP2K6/MKK6,MAP2K4/MKK4 and MAP2K7/MKK7. Activation by ultraviolet radiation,hyperosmotic shock, anisomycin or by TNF-alpha is mediated byMAP2K3/MKK3. Inhibited by dual specificity phosphatase DUSP1.{ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:9218798,ECO:0000269|PubMed:9374491}.SUBUNIT: Interacts with MAPK8IP2. {ECO:0000269|PubMed:11378392}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=O15264-1; Sequence=Displayed;Name=2;IsoId=O15264-2; Sequence=VSP_056558, VSP_056559;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in testes, pancreas, smallintestine, lung and kidney. Abundant in macrophages, also presentin neutrophils, CD4+ T-cells, and endothelial cells.{ECO:0000269|PubMed:10201954, ECO:0000269|PubMed:9374491}.DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Dually phosphorylated on Thr-180 and Tyr-182 by MAP2K3/MKK3,MAP2K4/MKK4, MAP2K6/MKK6 and MAP2K7/MKK7, which activates theenzyme. Dephosphorylated by dual specificity phosphatase DUSP1.{ECO:0000269|PubMed:9374491}.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK13ID41291ch6p21.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85541"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85541"]]}},{"data":{"id":"Protein_951a168f2858108577268f9a7615238b","class":"macromolecule","label":"MAPK12","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":445.01385,"y":305.28656,"w":48,"h":25},"metadata":[["bp:displayName","p38 gamma"],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P53778"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 185 185 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P53778"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 183 183 Phosphothreonine; by MAP2K3 and MAP2K6."],["bp:featureLocation","MOD_RES 183 183 Phosphothreonine; by MAP2K3 and MAP2K6."]]],["bp:standardName","Mitogen-activated protein kinase 12"],["bp:xref","Mitogen-activated protein kinase 12"],["bp:xref","Mitogen-activated protein kinase 12"],["bp:organism","Mitogen-activated protein kinase 12"],["bp:displayName","MK12_HUMAN"],["bp:name","ERK6"],["bp:name","MAP kinase p38 gamma"],["bp:name","MAPK 12"],["bp:name","MAP kinase 12"],["bp:name","2.7.11.24"],["bp:name","Stress-activated protein kinase 3"],["bp:name","MAPK12"],["bp:name","ERK-6"],["bp:name","SAPK3"],["bp:name","Extracellular signal-regulated kinase 6"],["bp:name","Mitogen-activated protein kinase p38 gamma"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1CM8_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03868_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34241N_identity"],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway. MAPK12 isone of the four p38 MAPKs which play an important role in thecascades of cellular responses evoked by extracellular stimulisuch as proinflammatory cytokines or physical stress leading todirect activation of transcription factors such as ELK1 and ATF2.Accordingly, p38 MAPKs phosphorylate a broad range of proteins andit has been estimated that they may have approximately 200 to 300substrates each. Some of the targets are downstream kinases suchas MAPKAPK2, which are activated through phosphorylation andfurther phosphorylate additional targets. Plays a role in myoblastdifferentiation and also in the down-regulation of cyclin D1 inresponse to hypoxia in adrenal cells suggesting MAPK12 may inhibitcell proliferation while promoting differentiation. PhosphorylatesDLG1. Following osmotic shock, MAPK12 in the cell nucleusincreases its association with nuclear DLG1, thereby causingdissociation of DLG1-SFPQ complexes. This function is independentof its catalytic activity and could affect mRNA processing and/orgene transcription to aid cell adaptation to osmolarity changes inthe environment. Regulates UV-induced checkpoint signaling andrepair of UV-induced DNA damage and G2 arrest after gamma-radiation exposure. MAPK12 is involved in the regulation of SLC2A1expression and basal glucose uptake in L6 myotubes; and negativelyregulates SLC2A4 expression and contraction-mediated glucoseuptake in adult skeletal muscle. C-Jun (JUN) phosphorylation isstimulated by MAPK14 and inhibited by MAPK12, leading to adistinct AP-1 regulation. MAPK12 is required for the normalkinetochore localization of PLK1, prevents chromosomal instabilityand supports mitotic cell viability. MAPK12-signaling is alsopositively regulating the expansion of transient amplifyingmyogenic precursor cells during muscle growth and regeneration.{ECO:0000269|PubMed:10848581, ECO:0000269|PubMed:14592936,ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:20605917,ECO:0000269|PubMed:21172807, ECO:0000269|PubMed:8633070,ECO:0000269|PubMed:9430721}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10212242}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10508788};Note=Binds 2 magnesium ions. {ECO:0000269|PubMed:10508788};ENZYME REGULATION: Activated by phosphorylation on threonine andtyrosine. MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for theactivation of MAPK12 induced by environmental stress, whereasMAP2K6/MKK6 is the major MAPK12 activator in response to TNF-alpha. {ECO:0000269|PubMed:10212242, ECO:0000269|PubMed:9430721}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=37 uM for ATP {ECO:0000269|PubMed:10212242};KM=313 uM for EGFR substrate peptide{ECO:0000269|PubMed:10212242};KM=254 uM for GST-ATF2 {ECO:0000269|PubMed:10212242};SUBUNIT: Monomer. Interacts with the PDZ domain of the syntrophinSNTA1. Interacts with SH3BP5. Interacts with LIN7C, SCRIB andSYNJ2BP (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Mitochondrion.Note=Mitochondrial when associated with SH3BP5. In skeletal musclecolocalizes with SNTA1 at the neuromuscular junction andthroughout the sarcolemma (By similarity). {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P53778-1; Sequence=Displayed;Name=2;IsoId=P53778-2; Sequence=VSP_055224;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Highly expressed in skeletal muscle and heart.{ECO:0000269|PubMed:11991731, ECO:0000269|PubMed:8633070}.INDUCTION: Expression of MAPK12 is down-regulation by MAPK14activation. {ECO:0000269|PubMed:17724032}.DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K3/MKK3and MAP2K6/MKK6, which activates the enzyme.{ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:17724032}.PTM: Ubiquitinated. Ubiquitination leads to degradation by theproteasome pathway. {ECO:0000269|PubMed:17724032}.DISEASE: Note=MAPK is overexpressed in highly metastatic breastcancer cell lines and its expression is preferentially associatedwith basal-like and metastatic phenotypes of breast tumor samples.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK12ID41290ch22q13.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002960"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6300"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_658"],["bp:comment","MK12_HUMAN Reviewed; 367 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85530"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85530"]]}},{"data":{"id":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":425.46103,"y":584.53326,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85536"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85535"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85535"]]}},{"data":{"id":"Protein_45ef0a50a907165e40ead96b9063fc1f","class":"macromolecule","label":"MAP2K6","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":182.69026,"y":288.40366,"w":48,"h":25},"metadata":[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES O-acetylthreonine"],["bp:term","O-acetylthreonine"]]],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 207 207 O-acetylserine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 207 207 O-acetylserine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]}},{"data":{"id":"Protein_fa319c70454228b2e585984dee82c803","class":"macromolecule","label":"MAPK12","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_fa319c70454228b2e585984dee82c803.info.1","class":"state variable","state":{"variable":"183","value":"opthr"}},{"id":"Protein_fa319c70454228b2e585984dee82c803.state.2","class":"state variable","state":{"variable":"185","value":"optyr"}},{"id":"Protein_fa319c70454228b2e585984dee82c803.info.3","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":495.92325,"y":492.71518,"w":85,"h":25},"metadata":[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85446"]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85446"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]}},{"data":{"id":"BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":629.16754,"y":524.76526,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Cyclin D1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85454"]]],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:xref","G1/S-specific cyclin-D1"],["bp:organism","G1/S-specific cyclin-D1"],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85453"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85456"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85452"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85452"]]}},{"data":{"id":"BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":376.6901,"y":766.977,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",null],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85543"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85540"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85540"]]}},{"data":{"id":"Protein_a70b78b946c922df4374be6199026b68","class":"macromolecule","label":"MAPT","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":344.60696,"y":533.4047,"w":48,"h":25},"metadata":[["bp:displayName","Tau"],["bp:entityReference_http://identifiers.org/uniprot/P10636",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P10636"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 739 739 Phosphoserine; by PDPK1 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","739"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 673 673 Phosphoserine; by MARK1; in PHF-tau."],["bp:featureLocation",[["bp:sequencePosition","673"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 733 733 Phosphoserine; by CaMK2 and TTBK1."],["bp:featureLocation",[["bp:sequencePosition","733"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:xref","Microtubule-associated protein tau"],["bp:organism","Microtubule-associated protein tau"],["bp:displayName","TAU_HUMAN"],["bp:name","PHF-tau"],["bp:name","Neurofibrillary tangle protein"],["bp:name","MTBT1"],["bp:name","MAPT"],["bp:name","Paired helical filament-tau"],["bp:name","MAPTL"],["bp:name","TAU"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-8"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3880"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P10636-2"],["bp:comment","TAU_HUMAN Reviewed; 758 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-2_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_4137"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_006725337"],["bp:comment","FUNCTION: Promotes microtubule assembly and stability, and mightbe involved in the establishment and maintenance of neuronalpolarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting thattau functions as a linker protein between both. Axonal polarity ispredetermined by TAU/MAPT localization (in the neuronal cell) inthe domain of the cell body defined by the centrosome. The shortisoforms allow plasticity of the cytoskeleton whereas the longerisoforms may preferentially play a role in its stabilization.{ECO:0000269|PubMed:21985311}.SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).Interacts with FKBP4 (By similarity). Binds to CSNK1D(PubMed:14761950). Interacts with SGK1 (PubMed:16982696).Interacts with EPM2A; the interaction dephosphorylates MAPT atSer-396 (PubMed:19542233). {ECO:0000250,ECO:0000269|PubMed:11313338, ECO:0000269|PubMed:14761950,ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19542233}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:10747907}. Cell membrane{ECO:0000269|PubMed:10747907}; Peripheral membrane protein{ECO:0000269|PubMed:10747907}; Cytoplasmic side{ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:10747907}. Cell projection, axon{ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons ofneurons, in the cytosol and in association with plasma membranecomponents.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=9;Comment=Additional isoforms seem to exist. Isoforms differ fromeach other by the presence or absence of up to 5 of the 15exons. One of these optional exons contains the additionaltau/MAP repeat.;Name=PNS-tau;IsoId=P10636-1; Sequence=Displayed;Name=Fetal-tau;IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180, VSP_003181;Name=Tau-A;IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,VSP_003178, VSP_003179, VSP_003180,VSP_003181;Name=Tau-B;IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,VSP_003181;Name=Tau-C; Synonyms=Tau-3;IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;Name=Tau-D;IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,VSP_003180;Name=Tau-E;IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;Name=Tau-F; Synonyms=Tau-4;IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;Name=Tau-G;IsoId=P10636-9; Sequence=VSP_026780;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau isexpressed in the peripheral nervous system while the others areexpressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressedin an adult-specific manner and is not found in fetal brain,whereas three-repeat (type I) TAU/MAPT is found in both adult andfetal brain.DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoformscontain 3 repeats while type II isoforms contain 4 repeats.PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-foldincrease in mitosis, and in the form associated with pairedhelical filaments (PHF-tau)), and at serine residues in K-X-G-Smotifs by MAP/microtubule affinity-regulating kinase (MARK1 orMARK2), causing detachment from microtubules, and theirdisassembly. Phosphorylation decreases with age. Phosphorylationwithin tau/MAP's repeat domain or in flanking regions seems toreduce tau/MAP's interaction with, respectively, microtubules orplasma membrane components. Phosphorylation on Ser-610, Ser-622,Ser-641 and Ser-673 in several isoforms during mitosis.Phosphorylation at Ser-548 by GSK3B reduces ability to bind andstabilize microtubules. Phosphorylation at Ser-579 by BRSK1 andBRSK2 in neurons affects ability to bind microtubules and plays arole in neuron polarization. Phosphorylated at Ser-554, Ser-579,Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 bySGK1 mediates microtubule depolymerization and neurite formationin hippocampal neurons. There is a reciprocal down-regulation ofphosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717completely abolishes the O-GlcNAcylation on this site, whilephosphorylation on Ser-713 and Ser-721 reduces glycosylation by afactor of 2 and 4 respectively. Phosphorylation on Ser-721 isreduced by about 41.5% by GlcNAcylation on Ser-717.Dephosphorylated at several serine and threonine residues by theserine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.PTM: Polyubiquitinated. Requires functional TRAF6 and may provokeSQSTM1-dependent degradation by the proteasome (By similarity).PHF-tau can be modified by three different forms ofpolyubiquitination. 'Lys-48'-linked polyubiquitination is themajor form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitinationalso occur. {ECO:0000250, ECO:0000269|PubMed:15953362,ECO:0000269|PubMed:16443603}.PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. Thereis reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes theO-GlcNAcylation on this site, while phosphorylation on Ser-713 andSer-721 reduces O-GlcNAcylation by a factor of 2 and 4respectively. O-GlcNAcylation on Ser-717 decreases thephosphorylation on Ser-721 by about 41.5%.{ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.Glycation is a non-enzymatic post-translational modification thatinvolves a covalent linkage between a sugar and an amino group ofa protein molecule forming ketoamine. Subsequent oxidation,fragmentation and/or cross-linking of ketoamine leads to theproduction of advanced glycation endproducts (AGES). Glycation mayplay a role in stabilizing PHF aggregation leading to tangleformation in AD.DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton inthe brain is progressively disrupted and replaced by tangles ofpaired helical filaments (PHF) and straight filaments, mainlycomposed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer diseasebrain cerebral cortex leading to an increase in TAU/MAPTphosphorylations. {ECO:0000269|PubMed:14517953,ECO:0000269|PubMed:26086902}.DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form ofdementia characterized by pathologic finding of frontotemporallobar degeneration, presenile dementia with behavioral changes,deterioration of cognitive capacities and loss of memory. In somecases, parkinsonian symptoms are prominent. Neuropathologicalchanges include frontotemporal atrophy often associated withatrophy of the basal ganglia, substantia nigra, amygdala. In mostcases, protein tau deposits are found in glial cells and/orneurons. {ECO:0000269|PubMed:10208578,ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10374757,ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10553987,ECO:0000269|PubMed:10802785, ECO:0000269|PubMed:11071507,ECO:0000269|PubMed:11117541, ECO:0000269|PubMed:11278002,ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:11921059,ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:12509859,ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:15883319,ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:26086902,ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,ECO:0000269|PubMed:9973279}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rareform of dementia pathologically defined by severe atrophy,neuronal loss and gliosis. It is characterized by the occurrenceof tau-positive inclusions, swollen neurons (Pick cells) andargentophilic neuronal inclusions known as Pick bodies thatdisproportionally affect the frontal and temporal corticalregions. Clinical features include aphasia, apraxia, confusion,anomia, memory loss and personality deterioration.{ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,ECO:0000269|PubMed:11891833}. Note=The disease is caused bymutations affecting the gene represented in this entry.DISEASE: Note=Defects in MAPT are a cause of corticobasaldegeneration (CBD). It is marked by extrapyramidal signs andapraxia and can be associated with memory loss. Neuropathologicfeatures may overlap Alzheimer disease, progressive supranuclearpalsy, and Parkinson disease.DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,pyramidal tract dysfunction, pseudobulbar signs and cognitivecapacities deterioration. Neurofibrillary tangles and gliosis butno amyloid plaques are found in diseased brains. Most cases appearto be sporadic, with a significant association with a commonhaplotype including the MAPT gene and the flanking regions.Familial cases show an autosomal dominant pattern of transmissionwith incomplete penetrance; genetic analysis of a few cases showedthe occurrence of tau mutations, including a deletion of Asn-613.{ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.Note=The disease is caused by mutations affecting the generepresented in this entry.DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: Asyndrome characterized by parkinsonism, tremor, rigidity,dementia, ophthalmoparesis and pyramidal signs. Neurofibrillarydegeneration occurs in the hippocampus, basal ganglia andbrainstem nuclei. Note=The disease is caused by mutationsaffecting the gene represented in this entry.WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;URL=\"http://www.alzforum.org/mutations/search?genes%255B%255D=348\";WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68of March 2006;URL=\"http://web.expasy.org/spotlight/back_issues/068\";WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;URL=\"https://en.wikipedia.org/wiki/Tau_protein\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058519"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3879"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3878"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1060"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P10636-6_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_3312"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_058525"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_4137"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29753N_identity"]]],["bp:name","TAU"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85430"]]}},{"data":{"id":"BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":515.5464999999999,"y":733.6367,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","eEF2K"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85464"],["bp:featureLocation",[["bp:sequencePosition","359"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12199"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11922"]]],["bp:entityReference_http://identifiers.org/uniprot/O00418",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 477 477 Phosphoserine."],["bp:featureLocation","MOD_RES 477 477 Phosphoserine."]]],["bp:standardName","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:xref","Eukaryotic elongation factor 2 kinase"],["bp:organism","Eukaryotic elongation factor 2 kinase"],["bp:displayName","EF2K_HUMAN"],["bp:name","2.7.11.20"],["bp:name","Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase"],["bp:name","EEF2K"],["bp:name","eEF-2 kinase"],["bp:name","eEF-2K"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_29904"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_84657"],["bp:comment","EF2K_HUMAN Reviewed; 725 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_29904"],["bp:comment","FUNCTION: Threonine kinase that regulates protein synthesis bycontrolling the rate of peptide chain elongation. Upon activationby a variety of upstream kinases including AMPK or TRPM7,phosphorylates the elongation factor EEF2 at a single site,renders it unable to bind ribosomes and thus inactive. In turn,the rate of protein synthesis is reduced.{ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:9144159}.CATALYTIC ACTIVITY: ATP + [elongation factor 2] = ADP +[elongation factor 2] phosphate. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:9144159}.ENZYME REGULATION: Undergoes calcium/calmodulin-dependentintramolecular autophosphorylation, and this results in itbecoming partially calcium/calmodulin-independent. {ECO:0000250}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=1.2 uM for EEF2 {ECO:0000269|PubMed:11015200};Vmax=4 nmol/min/mg enzyme {ECO:0000269|PubMed:11015200};SUBUNIT: Monomer or homodimer (Probable). Interacts withCalmodulin/CALM1; this interaction is strictly required forphosphorylation activity (PubMed:11015200).{ECO:0000269|PubMed:11015200, ECO:0000305}.PTM: Autophosphorylated at multiple residues, Thr-348 being themajor site. Phosphorylated by AMP-activated protein kinase AMPK atSer-398 leading to EEF2K activation and protein synthesisinhibition. Phosphorylated by TRPM7 at Ser-78 resulting inimproved protein stability, higher EE2F phosphorylated andsubsequently reduced rate of protein synthesis. Phosphorylation byother kinases such as CDK1 and MAPK13 at Ser-359 or RPS6KA1 andRPS6KB1 at Ser-366 instead decrease EEF2K activity and promoteprotein synthesis. {ECO:0000269|PubMed:11015200,ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11500364,ECO:0000269|PubMed:14709557, ECO:0000269|PubMed:18337751,ECO:0000269|PubMed:21112387, ECO:0000269|PubMed:22216903}.SIMILARITY: Belongs to the protein kinase superfamily. Alpha-typeprotein kinase family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_037434"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_591"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07369_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85463"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85466"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85462"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85462"]]}},{"data":{"id":"Protein_ff2c8b83b1fc77c13777abc7127a830b","class":"macromolecule","label":"MAP2K6","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_ff2c8b83b1fc77c13777abc7127a830b.info.1","class":"state variable","state":{"variable":"211","value":"opthr"}},{"id":"Protein_ff2c8b83b1fc77c13777abc7127a830b.state.2","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_ff2c8b83b1fc77c13777abc7127a830b.info.3","class":"state variable","state":{"variable":"207","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":333.2521,"y":322.651,"w":85,"h":25},"metadata":[["bp:displayName","MKK6"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15250"],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15251"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_46229"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15248"],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15249"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15248"],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15249"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_46228"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_46228"]]}},{"data":{"id":"Protein_c260141d14127cf9a10cc18fe4774e89","class":"macromolecule","label":"PKN1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_c260141d14127cf9a10cc18fe4774e89.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":120.824814,"y":23.363478,"w":48,"h":25},"metadata":[["bp:displayName","PKN"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14858"]]],["bp:entityReference_http://identifiers.org/uniprot/Q16512",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 778 778 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","778"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 914 914 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","914"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 448 448 N6-acetyllysine."],["bp:featureLocation","MOD_RES 448 448 N6-acetyllysine."]]],["bp:standardName","Serine/threonine-protein kinase N1"],["bp:xref","Serine/threonine-protein kinase N1"],["bp:xref","Serine/threonine-protein kinase N1"],["bp:organism","Serine/threonine-protein kinase N1"],["bp:displayName","PKN1_HUMAN"],["bp:name","PKN"],["bp:name","Protein kinase PKN-alpha"],["bp:name","PKN1"],["bp:name","Protein-kinase C-related kinase 1"],["bp:name","PAK1"],["bp:name","PRKCL1"],["bp:name","Serine-threonine protein kinase N"],["bp:name","Protein kinase C-like 1"],["bp:name","Protein kinase C-like PKN"],["bp:name","PRK1"],["bp:name","PAK-1"],["bp:name","Protease-activated kinase 1"],["bp:name","2.7.11.13"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011526430"],["bp:comment","REPLACED http://identifiers.org/uniprot/D0ZVG2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5585"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34240N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5585"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_650"],["bp:comment","FUNCTION: PKC-related serine/threonine-protein kinase involved invarious processes such as regulation of the intermediate filamentsof the actin cytoskeleton, cell migration, tumor cell invasion andtranscription regulation. Part of a signaling cascade that beginswith the activation of the adrenergic receptor ADRA1B and leads tothe activation of MAPK14. Regulates the cytoskeletal network byphosphorylating proteins such as VIM and neurofilament proteinsNEFH, NEFL and NEFM, leading to inhibit their polymerization.Phosphorylates 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau,lowering its ability to bind to microtubules, resulting indisruption of tubulin assembly. Acts as a key coactivator ofandrogen receptor (ANDR)-dependent transcription, by beingrecruited to ANDR target genes and specifically mediatingphosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specifictag for epigenetic transcriptional activation that promotesdemethylation of histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C.Phosphorylates HDAC5, HDAC7 and HDAC9, leading to impair theirimport in the nucleus. Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' of MARCKS, and GFAP. Able tophosphorylate RPS6 in vitro. {ECO:0000269|PubMed:11104762,ECO:0000269|PubMed:12514133, ECO:0000269|PubMed:17332740,ECO:0000269|PubMed:18066052, ECO:0000269|PubMed:20188095,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:21754995,ECO:0000269|PubMed:24248594, ECO:0000269|PubMed:8557118,ECO:0000269|PubMed:8621664, ECO:0000269|PubMed:9175763}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:18066052}.ENZYME REGULATION: Kinase activity is activated upon binding toRho proteins (RHOA, RHOB and RAC1). Activated by lipids,particularly cardiolipin and to a lesser extent by other acidicphospholipids. Activated by caspase-3 (CASP3) cleavage duringapoptosis. Two specific sites, Thr-774 (activation loop of thekinase domain) and Ser-916 (turn motif), need to be phosphorylatedfor its full activation. {ECO:0000269|PubMed:8571126,ECO:0000269|PubMed:9751706}.BIOPHYSICOCHEMICAL PROPERTIES:Kinetic parameters:KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095};SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts withANDR (PubMed:12514133). Interacts with PRKCB (PubMed:20228790).Interacts (via REM 1 and REM 2 repeats) with RAC1(PubMed:14514689, PubMed:18006505). Interacts (via REM 1 repeat)with RHOA (PubMed:10619026, PubMed:8571126). Interacts with RHOB(PubMed:9478917). Interacts (via C-terminus) with PDPK1(PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependenttranscription (PubMed:16331689). Component of a signaling complexcontaining at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Withinthis complex, AKAP13 interacts directly with PKN1, which in turnrecruits MAPK14, MAP2K3 and ZAK (PubMed:21224381).{ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026,ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133,ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689,ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126,ECO:0000269|PubMed:9478917}.SUBUNIT: (Microbial infection) Interacts (via the second REMrepeat) with S.typhimurium E3 ubiquitin-protein ligase SspH1 (viathe leucine-rich repeat region) (PubMed:16611232,PubMed:24248594). {ECO:0000269|PubMed:16611232,ECO:0000269|PubMed:24248594}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740,ECO:0000269|PubMed:9478917}. Nucleus{ECO:0000269|PubMed:12514133}. Endosome{ECO:0000269|PubMed:9478917}. Cell membrane{ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein{ECO:0000250|UniProtKB:Q63433}. Cleavage furrow{ECO:0000269|PubMed:17332740}. Midbody{ECO:0000269|PubMed:17332740}. Note=Associates with chromatin in aligand-dependent manner. Localization to endosomes is mediated viaits interaction with RHOB. Association to the cell membrane isdependent on Ser-377 phosphorylation. Accumulates during telophaseat the cleavage furrow and finally concentrates around the midbodyin cytokinesis. {ECO:0000250|UniProtKB:Q63433,ECO:0000269|PubMed:17332740}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1;IsoId=Q16512-1; Sequence=Displayed;Name=2;IsoId=Q16512-2; Sequence=VSP_038143;Note=No experimental confirmation available.;Name=3;IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain,placenta, lung, skeletal muscle, kidney and pancreas. Expressed innumerous tumor cell lines, especially in breast tumor cells.{ECO:0000269|PubMed:21754995}.DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).PTM: Autophosphorylated; preferably on serine. Phosphorylatedduring mitosis. {ECO:0000269|PubMed:10792047,ECO:0000269|PubMed:17332740}.PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}.PTM: (Microbial infection) In case of infection, polyubiquitinatedby the bacterial E3 ubiquitin-protein ligase SspH1, leading to itsproteasomal degradation. {ECO:0000269|PubMed:24248594}.SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. PKC subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","PKN1_HUMAN Reviewed; 942 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q16512_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14857"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_14857"]]}},{"data":{"id":"BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":423.49115,"y":391.44244,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","p38 gamma"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85447"],["bp:featureLocation",[["bp:sequencePosition","183"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2062"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P53778",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85448"],["bp:featureLocation",[["bp:sequencePosition","185"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2064"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85443"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87641"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_87639"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_87639"]]}},{"data":{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573","class":"macromolecule","label":"MAPK13","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573.info.1","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573.state.2","class":"state variable","state":{"variable":"182","value":"optyr"}},{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573.info.3","class":"state variable","state":{"variable":"180","value":"opthr"}}],"unitsOfInformation":[],"bbox":{"x":406.18875,"y":680.25665,"w":85,"h":25},"metadata":[["bp:displayName","p38 delta"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85471"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85473"],["bp:featureLocation",[["bp:sequencePosition","182"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2048"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation",[["bp:sequencePosition","180"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2029"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O15264",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85472"],["bp:featureLocation",[["bp:sequencePosition","180"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2029"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85468"]]}},{"data":{"id":"Protein_8918cfec9da6ffe40ad50cff9bed15eb","class":"macromolecule","label":"MAP3K20","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":34.233984,"y":126.904175,"w":48,"h":25},"metadata":[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation",[["bp:sequencePosition","165"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 649 649 Phosphoserine."],["bp:featureLocation","MOD_RES 649 649 Phosphoserine."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]}},{"data":{"id":"Protein_f4bafb8c1a807225acb16f2fb77de53a","class":"macromolecule","label":"SNTA1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":414.51044,"y":462.63013,"w":48,"h":25},"metadata":[["bp:displayName","SNTA1"],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 184 184 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 101 101 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","101"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 189 189 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","189"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 200 200 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","200"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 200 200 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","200"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:xref","Alpha-1-syntrophin"],["bp:organism","Alpha-1-syntrophin"],["bp:displayName","SNTA1_HUMAN"],["bp:name","59 kDa dystrophin-associated protein A1 acidic component 1"],["bp:name","SNTA1"],["bp:name","TACIP1"],["bp:name","Pro-TGF-alpha cytoplasmic domain-interacting protein 1"],["bp:name","Syntrophin-1"],["bp:name","SNT1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03009_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003089"],["bp:comment","FUNCTION: Adapter protein that binds to and probably organizes thesubcellular localization of a variety of membrane proteins. Maylink various receptors to the actin cytoskeleton and theextracellular matrix via the dystrophin glycoprotein complex.Plays an important role in synapse formation and in theorganization of UTRN and acetylcholine receptors at theneuromuscular synapse. Binds to phosphatidylinositol 4,5-bisphosphate (By similarity). {ECO:0000250}.SUBUNIT: Monomer and homodimer. Interacts with the other membersof the syntrophin family SNTB1 and SNTB2; SGCG and SGCA of thedystrophin glycoprotein complex; NOS1; GRB2; the sodium channelproteins SCN4A and SCN5A; F-actin and calmodulin (By similarity).Interacts with dystrophin protein DMD and related proteins DTNAand UTRN and with MAPK12, TGFA and GA. Interacts with MYOC;regulates muscle hypertrophy (By similarity). {ECO:0000250}.SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};Peripheral membrane protein {ECO:0000250}; Cytoplasmic side{ECO:0000250}. Cell junction {ECO:0000250}. Cytoplasm,cytoskeleton {ECO:0000250}. Note=In skeletal muscle, it localizesat the cytoplasmic side of the sarcolemmal membrane and atneuromuscular junctions. {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q13424-1; Sequence=Displayed;Name=2;IsoId=Q13424-2; Sequence=VSP_056827;Note=No experimental confirmation available.;TISSUE SPECIFICITY: High expression in skeletal muscle and heart.Low expression in brain, pancreas, liver, kidney and lung. Notdetected in placenta.DOMAIN: The PH 1 domain mediates the oligomerization in a calciumdependent manner, and the association with thephosphatidylinositol 4,5-bisphosphate. {ECO:0000250}.DOMAIN: The PDZ domain binds to the last three or four amino acidsof ion channels and receptor proteins. The association withdystrophin or related proteins probably leaves the PDZ domainavailable to recruit proteins to the membrane (By similarity).{ECO:0000250}.DOMAIN: The SU domain binds calmodulin in a calcium-dependentmanner. {ECO:0000250}.PTM: Phosphorylated by CaM-kinase II. Phosphorylation may inhibitthe interaction with DMD (By similarity). {ECO:0000250}.DISEASE: Long QT syndrome 12 (LQT12) [MIM:612955]: A heartdisorder characterized by a prolonged QT interval on the ECG andpolymorphic ventricular arrhythmias. They cause syncope and suddendeath in response to exercise or emotional stress, and can presentwith a sentinel event of sudden cardiac death in infancy.{ECO:0000269|PubMed:18591664, ECO:0000269|PubMed:19684871}.Note=The disease is caused by mutations affecting the generepresented in this entry.SIMILARITY: Belongs to the syntrophin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_Q13424_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-966N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16618"],["bp:comment","SNTA1_HUMAN Reviewed; 505 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6640"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85494"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85494"]]}},{"data":{"id":"ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":515.9390000000001,"y":417.41693,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","p38 gamma/SNTA1"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","SNTA1"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85500"],["bp:featureLocation",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:entityReference_http://identifiers.org/uniprot/Q13424",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85502"],["bp:featureLocation",[["bp:sequencePosition","201"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1055"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85499"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85503"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85497"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85508"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85493"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85493"]]}},{"data":{"id":"BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":276.14276,"y":253.18704,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_15240"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53476"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_53475"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_53475"]]}},{"data":{"id":"BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":131.64505,"y":117.850174,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85487"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85487"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85487"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85487"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85487"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MLK7"],["bp:entityReference_http://identifiers.org/uniprot/Q9NYL2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 628 628 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","628"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 567 567 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","567"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 165 165 Phosphoserine; by autocatalysis."],["bp:featureLocation","MOD_RES 165 165 Phosphoserine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:xref","Mitogen-activated protein kinase kinase kinase 20"],["bp:organism","Mitogen-activated protein kinase kinase kinase 20"],["bp:displayName","M3K20_HUMAN"],["bp:name","MLK-like mitogen-activated protein triple kinase"],["bp:name","MLK-related kinase"],["bp:name","2.7.11.25"],["bp:name","Human cervical cancer suppressor gene 4 protein"],["bp:name","ZAK"],["bp:name","MLTK"],["bp:name","Mixed lineage kinase-related kinase"],["bp:name","HCCS-4"],["bp:name","Leucine zipper- and sterile alpha motif-containing kinase"],["bp:name","Mitogen-activated protein kinase kinase kinase MLT"],["bp:name","MAP3K20"],["bp:name","MRK"],["bp:name","Sterile alpha motif- and leucine zipper-containing kinase AZK"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_799"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016859812"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9NYL2-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_51776"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_11791_identity"],["bp:comment","M3K20_HUMAN Reviewed; 800 AA."],["bp:comment","FUNCTION: Stress-activated component of a protein kinase signaltransduction cascade. Regulates the JNK and p38 pathways. Part ofa signaling cascade that begins with the activation of theadrenergic receptor ADRA1B and leads to the activation of MAPK14.Pro-apoptotic. Role in regulation of S and G2 cell cyclecheckpoint by direct phosphorylation of CHEK2 (PubMed:10924358,PubMed:11836244, PubMed:15342622, PubMed:21224381). Involved inlimb development (PubMed:26755636). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:11836244, ECO:0000269|PubMed:15342622,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.FUNCTION: Isoform 1: Phosphorylates histone H3 at 'Ser-28'(PubMed:15684425). May have role in neoplastic cell transformationand cancer development (PubMed:15172994). Causes cell shrinkageand disruption of actin stress fibers (PubMed:11042189).{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:15172994,ECO:0000269|PubMed:15684425}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:11836244}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:11836244};ENZYME REGULATION: Activated by phosphorylation by PKN1 andautophosphorylation on Thr-161 and Ser-165.{ECO:0000269|PubMed:11042189, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:15342622}.SUBUNIT: Homodimer (PubMed:10924358, PubMed:26755636). Interactswith PKN1 and ZNF33A (PubMed:12535642, PubMed:12761180). Componentof a signaling complex containing at least AKAP13, PKN1, MAPK14,MAP3K20 and MAP2K3. Within this complex, AKAP13 interacts directlywith PKN1, which in turn recruits MAPK14, MAP2K3 and MAP3K20(PubMed:21224381). {ECO:0000269|PubMed:10924358,ECO:0000269|PubMed:12535642, ECO:0000269|PubMed:12761180,ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:26755636}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15684425}.Nucleus {ECO:0000269|PubMed:15684425}. Note=Translocates to thenucleus upon ultraviolet B irradiation.{ECO:0000269|PubMed:15684425}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=1 {ECO:0000269|PubMed:11042189}; Synonyms=Alpha;IsoId=Q9NYL2-1; Sequence=Displayed;Name=2 {ECO:0000269|PubMed:11042189}; Synonyms=Beta;IsoId=Q9NYL2-2; Sequence=VSP_051743, VSP_051744;Note=Contains a phosphoserine at position 429.{ECO:0000269|PubMed:11042189};Name=3; Synonyms=HCCS-4;IsoId=Q9NYL2-3; Sequence=VSP_051741, VSP_051742;TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is thepredominant form in all tissues examined, except for liver, inwhich isoform 1 is more highly expressed.{ECO:0000269|PubMed:10924358, ECO:0000269|PubMed:11836244}.DISEASE: Split-foot malformation with mesoaxial polydactyly(SFMMP) [MIM:616890]: An autosomal recessive disordercharacterized by a split-foot defect, mesoaxial polydactyly, nailabnormalities of the hands, and sensorineural hearing loss.{ECO:0000269|PubMed:26755636}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=BAD92211.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_057737"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_51776"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85481"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85487"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85480"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85480"]]}},{"data":{"id":"Protein_96a6e264216d3d323322b25f8177d060","class":"macromolecule","label":"MAP2K3","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_96a6e264216d3d323322b25f8177d060.info.1","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_96a6e264216d3d323322b25f8177d060.state.2","class":"state variable","state":{"variable":"218","value":"opser"}},{"id":"Protein_96a6e264216d3d323322b25f8177d060.info.3","class":"state variable","state":{"variable":"222","value":"opthr"}}],"unitsOfInformation":[],"bbox":{"x":383.49445,"y":856.7711,"w":85,"h":25},"metadata":[["bp:displayName","MKK3"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21729"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15245"],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8442"]]]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15246"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_15246"],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8444"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_21728"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_21728"]]}},{"data":{"id":"Protein_57543599c805d78ca52320f8a94baa5f","class":"macromolecule","label":"STMN1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":228.97673,"y":712.48004,"w":48,"h":25},"metadata":[["bp:displayName","Stathmin"],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 100 100 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","100"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 38 38 Phosphoserine; by CDK1, MAPK1 and MAPK3."],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 4 4 Phosphoserine."],["bp:featureLocation","MOD_RES 4 4 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19183"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19183"]]}},{"data":{"id":"Protein_ec13cbda77bf715121ca252c8eaa9280","class":"macromolecule","label":"CCND1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":674.4405,"y":449.67255,"w":48,"h":25},"metadata":[["bp:displayName","Cyclin D1"],["bp:entityReference_http://identifiers.org/uniprot/P24385",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P24385"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","286"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P24385"]]],["bp:standardName","G1/S-specific cyclin-D1"],["bp:xref",[["bp:relationshipType",null],["bp:id","CCND1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P24385"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P24385"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","CCND1_HUMAN"],["bp:name","BCL-1"],["bp:name","BCL-1 oncogene"],["bp:name","PRAD1 oncogene"],["bp:name","B-cell lymphoma 1 protein"],["bp:name","BCL1"],["bp:name","CCND1"],["bp:name","PRAD1"],["bp:comment","FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}.SUBUNIT: Interacts with FBXO4 (By similarity). Interacts witheither CDK4 or CDK6 protein kinase to form a serine/threoninekinase holoenzyme complex. The cyclin subunit imparts substratespecificity to the complex. Component of the ternary complexCCND1/CDK4/CDKN1B required for nuclear translocation andmodulation of CDK4-mediated kinase activity. Interacts directlywith CDKN1B. Interacts with UHRF2; the interaction ubiquitinatesCCND1 and appears to occur independently of phosphorylation. Canform similar complexes with either CDKN1A or CDKN2A. Interactswith USP2. Interacts (via cyclin N-terminal domain) with INSM1(via N-terminal region); the interaction competes with the bindingof CCND1 to CDK4 during cell cycle progression and inhibits CDK4activity. Interacts with CDK4; the interaction is prevented withthe binding of CCND1 to INSM1 during cell cycle progression.{ECO:0000250, ECO:0000269|PubMed:16569215,ECO:0000269|PubMed:18417529, ECO:0000269|PubMed:19124461,ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19917254,ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:8302605,ECO:0000269|PubMed:9106657}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9106657}.Cytoplasm {ECO:0000269|PubMed:9106657}. Membrane{ECO:0000269|PubMed:9106657}. Note=Cyclin D-CDK4 complexesaccumulate at the nuclear membrane and are then translocated tothe nucleus through interaction with KIP/CIP family members.{ECO:0000250}.PTM: Phosphorylation at Thr-286 by MAP kinases is required forubiquitination and degradation following DNA damage. It probablyplays an essential role for recognition by the FBXO31 component ofSCF (SKP1-cullin-F-box) protein ligase complex.{ECO:0000269|PubMed:19412162, ECO:0000269|PubMed:19917254}.PTM: Ubiquitinated, primarily as 'Lys-48'-linkedpolyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-boxprotein) ubiquitin-protein ligase complex containing FBXO4 andCRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-typeubiquitination is dependent on Thr-286 phosphorylation (Bysimilarity). Ubiquitinated also by UHRF2 apparently in aphosphorylation-independent manner. Ubiquitination leads to itsdegradation and G1 arrest. Deubiquitinated by USP2; leading to itsstabilization. {ECO:0000250, ECO:0000269|PubMed:19412162,ECO:0000269|PubMed:19917254}.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of B-lymphocytic malignancy, particularly mantle-celllymphoma (MCL). Translocation t(11;14)(q13;q32) withimmunoglobulin gene regions. Activation of CCND1 may be oncogenicby directly altering progression through the cell cycle.DISEASE: Note=A chromosomal aberration involving CCND1 may be acause of parathyroid adenomas. Translocation t(11;11)(q13;p15)with the parathyroid hormone (PTH) enhancer.DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor ofplasma cells usually arising in the bone marrow and characterizedby diffuse involvement of the skeletal system, hyperglobulinemia,Bence-Jones proteinuria and anemia. Complications of multiplemyeloma are bone pain, hypercalcemia, renal failure and spinalcord compression. The aberrant antibodies that are produced leadto impaired humoral immunity and patients have a high prevalenceof infection. Amyloidosis may develop in some patients. Multiplemyeloma is part of a spectrum of diseases ranging from monoclonalgammopathy of unknown significance (MGUS) to plasma cell leukemia.{ECO:0000269|PubMed:8695815}. Note=The gene represented in thisentry is involved in disease pathogenesis. A chromosomalaberration involving CCND1 is found in multiple myeloma.Translocation t(11;14)(q13;q32) with the IgH locus.SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/BCL1ID36.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/ccnd1/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_642812"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1166"],["bp:comment","REPLACED ProteinRef_CCND1__10116"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_444284"],["bp:comment","CCND1_HUMAN Reviewed; 295 AA."],["bp:comment","REPLACED ProteinRef_CCND1__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_595"],["bp:comment","REPLACED ProteinRef_CCND1__9606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_595"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-123N_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_45323"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_45323"]]}},{"data":{"id":"Protein_06f2fa343fa3586c55409401d70a458f","class":"macromolecule","label":"STMN1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_06f2fa343fa3586c55409401d70a458f.info.1","class":"state variable","state":{"variable":"25","value":"opser"}},{"id":"Protein_06f2fa343fa3586c55409401d70a458f.state.2","class":"state variable","state":{"variable":"38","value":"opser"}}],"unitsOfInformation":[],"bbox":{"x":233.3982,"y":562.9689,"w":48,"h":25},"metadata":[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","31"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]}},{"data":{"id":"BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":284.65976,"y":642.2703,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Stathmin"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00046"],["bp:db","protein modification ontology"]]],["bp:term","opser"],["bp:term","O-phospho-L-serine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85522"],["bp:featureLocation",[["bp:sequencePosition","25"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_14216"]]]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85523"],["bp:featureLocation",[["bp:sequencePosition","38"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_26066"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P16949",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 31 31 Phosphoserine."],["bp:featureLocation","MOD_RES 31 31 Phosphoserine."]]],["bp:standardName","Stathmin"],["bp:xref","Stathmin"],["bp:xref","Stathmin"],["bp:organism","Stathmin"],["bp:displayName","STMN1_HUMAN"],["bp:name","Metablastin"],["bp:name","pp19"],["bp:name","pp17"],["bp:name","Op18"],["bp:name","Protein Pr22"],["bp:name","LAP18"],["bp:name","Phosphoprotein p19"],["bp:name","OP18"],["bp:name","Leukemia-associated phosphoprotein p18"],["bp:name","C1orf215"],["bp:name","Oncoprotein 18"],["bp:name","STMN1"],["bp:name","Prosolin"],["bp:comment","STMN1_HUMAN Reviewed; 149 AA."],["bp:comment","FUNCTION: Involved in the regulation of the microtubule (MT)filament system by destabilizing microtubules. Prevents assemblyand promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.Involved in the control of the learned and innate fear (Bysimilarity). {ECO:0000250}.SUBUNIT: Binds to two alpha/beta-tubulin heterodimers. Interactswith KIST. {ECO:0000269|PubMed:10675326,ECO:0000269|PubMed:10702243}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P16949-1; Sequence=Displayed;Name=2;IsoId=P16949-2; Sequence=VSP_041377;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous. Expression is strongest in fetaland adult brain, spinal cord, and cerebellum, followed by thymus,bone marrow, testis, and fetal liver. Expression is intermediatein colon, ovary, placenta, uterus, and trachea, and is readilydetected at substantially lower levels in all other tissuesexamined. Lowest expression is found in adult liver. Present inmuch greater abundance in cells from patients with acute leukemiaof different subtypes than in normal peripheral blood lymphocytes,non-leukemic proliferating lymphoid cells, bone marrow cells, orcells from patients with chronic lymphoid or myeloid leukemia.{ECO:0000269|PubMed:12676564, ECO:0000269|PubMed:1917919}.INDUCTION: Down-regulated in response to enterovirus 71 (EV71)infection (at protein level). {ECO:0000269|PubMed:16548883}.PTM: Many different phosphorylated forms are observed depending onspecific combinations among the sites which can be phosphorylated.MAPK is responsible for the phosphorylation of stathmin inresponse to NGF. Phosphorylation at Ser-16 seems to be requiredfor neuron polarization (By similarity). Phosphorylation at Ser-63reduces tubulin binding 10-fold and suppresses the MTpolymerization inhibition activity. {ECO:0000250,ECO:0000269|PubMed:1737801, ECO:0000269|PubMed:8125092,ECO:0000269|PubMed:8245003, ECO:0000269|PubMed:8325880}.SIMILARITY: Belongs to the stathmin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3925"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01047_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_005554"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_STMN1"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1532"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3925"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85521"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85520"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_85520"]]}}],"edges":[{"data":{"id":"Protein_06fde557217dbf75b819191c370cb967--to--BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_06fde557217dbf75b819191c370cb967","target":"BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_06fde557217dbf75b819191c370cb967","portTarget":"BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_c6374c3394d83a9ecd4b7c9f5c37582e--to--BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_c6374c3394d83a9ecd4b7c9f5c37582e","target":"BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_c6374c3394d83a9ecd4b7c9f5c37582e","portTarget":"InputPort_BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT-output--to--Protein_8af30cafb4713e68f6f66ed190a6e573","class":"production","cardinality":0,"source":"BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT","target":"Protein_8af30cafb4713e68f6f66ed190a6e573","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT","portTarget":"Protein_8af30cafb4713e68f6f66ed190a6e573"}},{"data":{"id":"BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT-output--to--Protein_fa319c70454228b2e585984dee82c803","class":"production","cardinality":0,"source":"BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT","target":"Protein_fa319c70454228b2e585984dee82c803","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT","portTarget":"Protein_fa319c70454228b2e585984dee82c803"}},{"data":{"id":"BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT-output--to--Protein_ff2c8b83b1fc77c13777abc7127a830b","class":"production","cardinality":0,"source":"BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT","target":"Protein_ff2c8b83b1fc77c13777abc7127a830b","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT","portTarget":"Protein_ff2c8b83b1fc77c13777abc7127a830b"}},{"data":{"id":"Protein_c260141d14127cf9a10cc18fe4774e89--to--BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_c260141d14127cf9a10cc18fe4774e89","target":"BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_c260141d14127cf9a10cc18fe4774e89","portTarget":"BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_f4bafb8c1a807225acb16f2fb77de53a--to--ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f4bafb8c1a807225acb16f2fb77de53a","target":"ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f4bafb8c1a807225acb16f2fb77de53a","portTarget":"InputPort_ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT-output--to--Protein_edfcca4699b5b1e52a7a1c42a1af5814","class":"production","cardinality":0,"source":"BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT","target":"Protein_edfcca4699b5b1e52a7a1c42a1af5814","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT","portTarget":"Protein_edfcca4699b5b1e52a7a1c42a1af5814"}},{"data":{"id":"Protein_ec13cbda77bf715121ca252c8eaa9280--to--BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_ec13cbda77bf715121ca252c8eaa9280","target":"BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ec13cbda77bf715121ca252c8eaa9280","portTarget":"InputPort_BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_45ef0a50a907165e40ead96b9063fc1f--to--BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_45ef0a50a907165e40ead96b9063fc1f","target":"BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_45ef0a50a907165e40ead96b9063fc1f","portTarget":"InputPort_BiochemicalReaction_f4b555c246c60968ca7c08ceee478549_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573--to--BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_8af30cafb4713e68f6f66ed190a6e573","target":"BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_8af30cafb4713e68f6f66ed190a6e573","portTarget":"BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff2c8b83b1fc77c13777abc7127a830b--to--BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff2c8b83b1fc77c13777abc7127a830b","target":"BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff2c8b83b1fc77c13777abc7127a830b","portTarget":"BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a70b78b946c922df4374be6199026b68--to--BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_a70b78b946c922df4374be6199026b68","target":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a70b78b946c922df4374be6199026b68","portTarget":"InputPort_BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT-output--to--Complex_55ee9b8dc7db84a0b99df71bdb152cd0","class":"production","cardinality":0,"source":"ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT","target":"Complex_55ee9b8dc7db84a0b99df71bdb152cd0","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT","portTarget":"Complex_55ee9b8dc7db84a0b99df71bdb152cd0"}},{"data":{"id":"Protein_57543599c805d78ca52320f8a94baa5f--to--BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_57543599c805d78ca52320f8a94baa5f","target":"BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_57543599c805d78ca52320f8a94baa5f","portTarget":"InputPort_BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_fa319c70454228b2e585984dee82c803--to--ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_fa319c70454228b2e585984dee82c803","target":"ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_fa319c70454228b2e585984dee82c803","portTarget":"InputPort_ComplexAssembly_c01f9b9a8c51a09615ebac10da19fac6_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT-output--to--Protein_3e52553453b56c182c0d978bccafe30a","class":"production","cardinality":0,"source":"BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT","target":"Protein_3e52553453b56c182c0d978bccafe30a","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT","portTarget":"Protein_3e52553453b56c182c0d978bccafe30a"}},{"data":{"id":"Protein_fa319c70454228b2e585984dee82c803--to--BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_fa319c70454228b2e585984dee82c803","target":"BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_fa319c70454228b2e585984dee82c803","portTarget":"BiochemicalReaction_a91d03ffa4cfbc88e25798077084bfe6_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_951a168f2858108577268f9a7615238b--to--BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_951a168f2858108577268f9a7615238b","target":"BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_951a168f2858108577268f9a7615238b","portTarget":"InputPort_BiochemicalReaction_476a6391c58eb8b4ebdf9cf4383f01ca_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_fa319c70454228b2e585984dee82c803--to--BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_fa319c70454228b2e585984dee82c803","target":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_fa319c70454228b2e585984dee82c803","portTarget":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT-output--to--Protein_58ad31ea01610e5c631e55d7e995ea39","class":"production","cardinality":0,"source":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","target":"Protein_58ad31ea01610e5c631e55d7e995ea39","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","portTarget":"Protein_58ad31ea01610e5c631e55d7e995ea39"}},{"data":{"id":"Protein_ac3f1d876372d67ec808fa0e78f8f12e--to--BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_ac3f1d876372d67ec808fa0e78f8f12e","target":"BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ac3f1d876372d67ec808fa0e78f8f12e","portTarget":"InputPort_BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573--to--BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_8af30cafb4713e68f6f66ed190a6e573","target":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_8af30cafb4713e68f6f66ed190a6e573","portTarget":"BiochemicalReaction_5edadb83cb71e8182103db5cb31cb5b2_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_8af30cafb4713e68f6f66ed190a6e573--to--BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_8af30cafb4713e68f6f66ed190a6e573","target":"BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_8af30cafb4713e68f6f66ed190a6e573","portTarget":"BiochemicalReaction_835e5ed6a121444cef8a8076d40d4701_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_96a6e264216d3d323322b25f8177d060--to--BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_96a6e264216d3d323322b25f8177d060","target":"BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_96a6e264216d3d323322b25f8177d060","portTarget":"BiochemicalReaction_2a56b71f725f0d483d7d215016bc871a_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT-output--to--Protein_06fde557217dbf75b819191c370cb967","class":"production","cardinality":0,"source":"BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT","target":"Protein_06fde557217dbf75b819191c370cb967","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT","portTarget":"Protein_06fde557217dbf75b819191c370cb967"}},{"data":{"id":"Protein_8918cfec9da6ffe40ad50cff9bed15eb--to--BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_8918cfec9da6ffe40ad50cff9bed15eb","target":"BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_8918cfec9da6ffe40ad50cff9bed15eb","portTarget":"InputPort_BiochemicalReaction_1824ba28feb5523c6c321bc532117f87_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT-output--to--Protein_06f2fa343fa3586c55409401d70a458f","class":"production","cardinality":0,"source":"BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT","target":"Protein_06f2fa343fa3586c55409401d70a458f","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_4fb5979fea60e716cdfa5ce3e673d6c4_LEFT_TO_RIGHT","portTarget":"Protein_06f2fa343fa3586c55409401d70a458f"}}],"pathwayMetadata":{"comments":["REPLACED http://pid.nci.nih.gov/biopax#pid_85428"],"dataSource":["pid"],"title":["Signaling mediated by p38-gamma and p38-delta"]}}